Emerging data suggest this peptide, a dual agonist targeting both the gut-brain axis and GIP , may represent a promising development for obesity loss . Early patient investigations have shown substantial decreases in body mass , possibly exceeding existing body composition medications . Nevertheless , additional study is needed to completely det… Read More